severe osteoporosis
Endocrinology · 2018–2024
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| romosozumab Treatment of severe established osteoporosis in postmenopausal women and men at very high risk of fracture (defined as BMD T-score ≤-2.5 with recent hip or… | Mar 2024 | Recommended with restriction | input received Healthy Bones Australia |
| romosozumab Treatment of severe established osteoporosis in patients at very high risk of fracture, defined by BMD T-score ≤-2.5 and fracture history criteria (recent… | Mar 2023 | Recommended with restriction | 1 individuals Healthy Bones Australia · Bones Australia · Musculoskeletal Australia · CreakyJoints Australia |
| romosozumab Treatment of severe osteoporosis in patients with multiple minimal trauma fractures, at least one symptomatic fracture, and BMD T-score ≤ -3.0. | Nov 2018 | Not recommended | input received Osteoporosis Australia |
Who spoke
Healthy Bones Australia · Osteoporosis Australia · Bones Australia · Musculoskeletal Australia · CreakyJoints Australia
What the PBS pays
$5M in government benefit over 2024–25, across 13,508 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| romosozumab | $5.3M |
Appraised elsewhere
NICE, in England and Wales, has appraised 1 technology for this condition, recommending 1 . A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| romosozumabRomosozumab for treating severe osteoporosis | TA791 | recommended restricted | 2022-05 |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 3 of 3 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.